APG vs GPN

The Advanced Deterministic Scorecard reveals a weak financial health profile with a Piotroski F-Score of 4/9, indicating borderline stability, and a missing Altman Z-Score prevents a full solvency assessment. Despite strong recent price performance and robust revenue and earnings growth, the stock trades at a steep valuation (P/E of 116.19 vs. sector average of 48.97) far above its Graham Number of $7.99 and intrinsic value of $10.62, suggesting significant overvaluation. Earnings quality is deteriorating, with 3 of the last 4 quarters missing estimates by an average of -32.33%, and YoY EPS has declined by 41.2% despite positive Q/Q growth. Heavy insider selling of $20.69M in the last 6 months and a bearish technical trend further reinforce caution.

GPN presents a stark contrast between strong deterministic health and deteriorating growth. While the Piotroski F-Score of 7/9 indicates robust financial health and the stock trades significantly below its Graham Number ($98.18) and book value (P/B 0.71), these value metrics are countered by a severe collapse in earnings growth (-59.20% YoY) and a bearish technical trend (0/100). The massive discrepancy between the current P/E (15.42) and Forward P/E (4.22) suggests the market is pricing in a recovery that is not yet evident in the quarterly data. Consequently, the stock appears to be a deep-value play with significant execution risk.